Eagle Pharmaceuticals Reports Second Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80
August 9, 2022 7:26 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $1.56, $1.80 worse than the analyst estimate of $3.36. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $116.95 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More